← Back to Patent Explorer
US4382925A Expired / Lapsed US ⏱️ 0.0 years remaining

E-5-(2-Halogenovinyl)-2'-deoxycytidines

Assignee: Stichting Rega VZW
•
Filing: 1980-10-02
•
Granted: 1983-05-10
•
Expires: 2000-10-02
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to E-5-(2-halogenovinyl)-2'-deoxycytidines, e.g. E-5-(bromovinyl)-2'-deoxycytidine and E-5-(2-iodovinyl)-2'-deoxycytidine. These substances are endowed with specific antiviral activities towards herpes simplex virus and with an extremely low toxicity which makes them useful in antiviral medicines and for treatment of virus diseases in man and animal. They may be synthesized by introduction of an E-5-(2-halogenovinyl) sidechain into 2'-deoxycytidine, or by condensation of a trialkylsilyl derivative of E-5-(2-halogenovinyl)-cytosine with a hydroxyl-protected reactive derivative of 2'-deoxy-D-erythro-pentofuranose.

Inventors

  • 👤 Erik De Clercq
  • 👤 Gabriel A. Verhelst
  • 👤 Albert S. Jones
  • 👤 Richard T. Walker

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 01:45
CPC Classifications
C; C07; C07H; C07H19/00; C07H19/02; C07H19/04; C07H19/06; A; A61; A61P; A61P31/00; A61P31/12

Claims Analysis

Total Claims: 8
Claim 1
Independent Claim 12 words
E-5-(2-halogenovinyl)-2'-deoxycytidines selected, in particular, from the group consisting of E-5-(2-bromovinyl)-2'-deoxycytidine and E-5-(2-iodovinyl)-2'deoxycytidine.
Claim 2
Dependent Claim 12 words
E-5-(2-halogenovinyl)-2'-deoxycytidines selected, in particular, from the group consisting of E-5-(2-bromovinyl)-2'-deoxycytidine and E-5-(2-iodovinyl)-2'deoxycytidine.
Claim 3
Independent Claim 44 words
A method of preparing an E-5-(2-halogenovinyl)-2'-deoxycytidine which comprises introducing an E-5-(2-halogenovinyl)-group into 2'-deoxycytidine by the steps of reacting 5-chloromercuri-2'-deoxycytidine with an ethyl acrylate in the presence of a lithium palladium chloride catalyst, hydrolyzing the resulting E-5-(2-carbethoxyvinyl)-2'deoxycytidine and halogenating the resulting E-5-(2-carboxyvinyl)-2'-deoxycytidine to form E-5-(2-halogenovinyl)-2'-deoxycytidine.
Claim 4
Independent Claim 44 words
A method of preparing an E-5-(2-halogenovinyl)-2'-deoxycytidine which comprises introducing an E-5-(2-halogenovinyl)-group into 2'-deoxycytidine by the steps of reacting 5-chloromercuri-2'-deoxycytidine with an ethyl acrylate in the presence of a lithium palladium chloride catalyst, hydrolyzing the resulting E-5-(2-carbethoxyvinyl)-2'deoxycytidine and halogenating the resulting E-5-(2-carboxyvinyl)-2'-deoxycytidine to form E-5-(2-halogenovinyl)-2'-deoxycytidine.
Claim 5
Independent Claim 24 words
A method of treating herpes simplex infections, which comprises administering a therapeutically effective amount of E-5-(2-halogenovinyl)-2'-deoxycytidine to a patient suffering from herpes simplex infection.
Claim 6
Independent Claim 24 words
A method of treating herpes simplex infections, which comprises administering a therapeutically effective amount of E-5-(2-halogenovinyl)-2'-deoxycytidine to a patient suffering from herpes simplex infection.
Claim 7
Dependent Claim 38 words
An antiviral pharmaceutical composition having special usefulness for treatment of herpes simplex infections, said pharmaceutical composition comprising an effective amount of E-5-(2-halogenovinyl)-2'-deoxycytidine, selected in particular from the group consisiting of E-5-(2-bromovinyl)-2'-deoxycytidine and E-5-(2-iodovinyl)-2'-deoxycytidine with a pharmaceutically acceptable excipient.
Claim 8
Dependent Claim 38 words
An antiviral pharmaceutical composition having special usefulness for treatment of herpes simplex infections, said pharmaceutical composition comprising an effective amount of E-5-(2-halogenovinyl)-2'-deoxycytidine, selected in particular from the group consisiting of E-5-(2-bromovinyl)-2'-deoxycytidine and E-5-(2-iodovinyl)-2'-deoxycytidine with a pharmaceutically acceptable excipient.

References Cited (Backward Citations)

US3354160A Cited
US4000260A Cited
US4024143A Cited
US4267171A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1986-05-09 1986-11-08 1987-05-10 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1990-05-09 1990-11-08 1991-05-10 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1994-05-09 1994-11-08 1995-05-10 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag